GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CNBX Pharmaceuticals Inc (OTCPK:CNBX) » Definitions » Current Ratio

CNBX Pharmaceuticals (CNBX Pharmaceuticals) Current Ratio : 0.07 (As of Feb. 2024)


View and export this data going back to 2007. Start your Free Trial

What is CNBX Pharmaceuticals Current Ratio?

The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. CNBX Pharmaceuticals's current ratio for the quarter that ended in Feb. 2024 was 0.07.

CNBX Pharmaceuticals has a current ratio of 0.07. It indicates that the company may have difficulty meeting its current obligations. Low values, however, do not indicate a critical problem. If CNBX Pharmaceuticals has good long-term prospects, it may be able to borrow against those prospects to meet current obligations.

The historical rank and industry rank for CNBX Pharmaceuticals's Current Ratio or its related term are showing as below:

CNBX' s Current Ratio Range Over the Past 10 Years
Min: 0.04   Med: 1.06   Max: 17.53
Current: 0.07

During the past 13 years, CNBX Pharmaceuticals's highest Current Ratio was 17.53. The lowest was 0.04. And the median was 1.06.

CNBX's Current Ratio is ranked worse than
97.43% of 1557 companies
in the Biotechnology industry
Industry Median: 3.73 vs CNBX: 0.07

CNBX Pharmaceuticals Current Ratio Historical Data

The historical data trend for CNBX Pharmaceuticals's Current Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CNBX Pharmaceuticals Current Ratio Chart

CNBX Pharmaceuticals Annual Data
Trend Aug14 Aug15 Aug16 Aug17 Aug18 Aug19 Aug20 Aug21 Aug22 Aug23
Current Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 9.81 2.04 1.25 0.08 0.09

CNBX Pharmaceuticals Quarterly Data
May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24
Current Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.04 0.14 0.09 0.06 0.07

Competitive Comparison of CNBX Pharmaceuticals's Current Ratio

For the Biotechnology subindustry, CNBX Pharmaceuticals's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CNBX Pharmaceuticals's Current Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CNBX Pharmaceuticals's Current Ratio distribution charts can be found below:

* The bar in red indicates where CNBX Pharmaceuticals's Current Ratio falls into.



CNBX Pharmaceuticals Current Ratio Calculation

The current ratio is mainly used to give an idea of the company's ability to pay back its short-term liabilities with its short-term assets.

CNBX Pharmaceuticals's Current Ratio for the fiscal year that ended in Aug. 2023 is calculated as

Current Ratio (A: Aug. 2023 )=Total Current Assets (A: Aug. 2023 )/Total Current Liabilities (A: Aug. 2023 )
=0.224/2.516
=0.09

CNBX Pharmaceuticals's Current Ratio for the quarter that ended in Feb. 2024 is calculated as

Current Ratio (Q: Feb. 2024 )=Total Current Assets (Q: Feb. 2024 )/Total Current Liabilities (Q: Feb. 2024 )
=0.164/2.522
=0.07

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


CNBX Pharmaceuticals  (OTCPK:CNBX) Current Ratio Explanation

The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.

Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.

The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.

If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.


CNBX Pharmaceuticals Current Ratio Related Terms

Thank you for viewing the detailed overview of CNBX Pharmaceuticals's Current Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


CNBX Pharmaceuticals (CNBX Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
No. 3 Bethesda Metro Center, Suite 700, Bethesda, MD, USA, 20814
CNBX Pharmaceuticals Inc is a biotechnology company. It develops pharmaceuticals focusing on cancer research utilizing HTS technology and personalized bioinformatics tools. The company's main focus is the development of cannabinoid therapies and other technologies for the treatment of cancer, mainly cancers of the gastrointestinal tract, skin, breast, and prostate. The firm's main product is the RCC-33, an oral capsule for the treatment of colorectal cancer. The company tools include delivery systems, personalized medicine diagnostics, and therapies based on Cannabinoid compounds.
Executives
Cannabics Inc. 10 percent owner 108 WEST 13TH ST., WILMINGTON DE 19801
Thomas E Mills director, officer: President, CEO, CFO
North American Mining Corp 10 percent owner 6767 WEST TROPICANA AVENUE, SUITE 229, LAS VEGAS NV 89103
Lou Hilford director, officer: Vice-President, Secretary